Compare NNI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | ACAD |
|---|---|---|
| Founded | 1978 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 2003 | 2004 |
| Metric | NNI | ACAD |
|---|---|---|
| Price | $128.76 | $26.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 21 |
| Target Price | ★ $135.00 | $29.24 |
| AVG Volume (30 Days) | 119.6K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 288.59 | 98.53 |
| EPS | ★ 11.91 | 1.54 |
| Revenue | ★ $1,698,851,000.00 | $1,047,118,000.00 |
| Revenue This Year | $11.74 | $15.16 |
| Revenue Next Year | $6.27 | $11.42 |
| P/E Ratio | ★ $10.96 | $17.36 |
| Revenue Growth | ★ 35.52 | 12.69 |
| 52 Week Low | $98.15 | $13.40 |
| 52 Week High | $136.68 | $27.73 |
| Indicator | NNI | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 68.71 |
| Support Level | $129.36 | $22.81 |
| Resistance Level | $134.39 | $25.20 |
| Average True Range (ATR) | 3.20 | 0.86 |
| MACD | 0.23 | 0.28 |
| Stochastic Oscillator | 57.05 | 80.06 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.